Stay updated with breaking news from Acorda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the
Johnson afirma que volen garantir un pas segur de sortida Von der Leyen assenyala que el reconeixement del règim talibà no està sobre la taula
L'Audiència de Girona acorda l'expulsió del país de l'acusat quan accedeixi al tercer grau o a la llibertat condicional
Acorda: Q4 Earnings Snapshot FacebookTwitterEmail ARDSLEY, N.Y. (AP) _ Acorda Therapeutics Inc. (ACOR) on Thursday reported fourth-quarter profit of $83 million. On a per-share basis, the Ardsley, New York-based company said it had net income of $9.82. Losses, adjusted for non-recurring gains, came to $2.50 per share. The drugmaker posted revenue of $38.2 million in the period. For the year, the company reported that its loss narrowed to $99.6 million, or $12.32 per share. Revenue was reported as $153 million. Acorda shares have climbed 64% since the beginning of the year. In the final minute...
Acorda Rises On Restructuring, ALXN Pauses COVID-19 Trial, SYBX On Watch Read on. 1. Acorda Rises on Corporate Restructuring Shares of Acorda Therapeutics Inc. (ACOR) jumped over 44% on Wednesday, on news of the company agreeing to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent, Inc. (CTLT) for $80 million in cash. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinson's disease treated with regular carbidopa/levodopa medicine. The companies have also inked a long-ter...